Trust signals
> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited
Key Takeaways
- Wegovy received FDA approval on June 4, 2021, making it 4 years and 10 months old as of April 2026
- The medication faced severe supply shortages from March 2022 through October 2023, limiting patient access for 19 months
- Semaglutide itself (the active ingredient) was approved for diabetes as Ozempic in December 2017, giving the molecule 8+ years of real-world safety data
- The compounded semaglutide market emerged during Wegovy shortages and remains active in 2026 despite restored brand-name supply
Direct answer (40-60 words)
Wegovy has been on the U.S. market since June 4, 2021, when the FDA approved it for chronic weight management. As of April 2026, the medication is 4 years and 10 months old. However, semaglutide (the active ingredient) has been available since 2017 as Ozempic for diabetes, providing nearly 9 years of accumulated clinical experience with the molecule.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of contents
- The official FDA approval date and what it means
- The complete Wegovy timeline: 2021 to 2026
- Why the approval date doesn't tell the full story
- The shortage period: when Wegovy disappeared and why it matters
- How Wegovy's market age compares to other GLP-1 medications
- What most articles get wrong about "how long Wegovy has been studied"
- The compounded semaglutide response: a parallel timeline
- What 5 years of real-world data has revealed
- The supply stability question: where things stand in 2026
- How to interpret "time on market" when choosing a GLP-1 medication
- FAQ
- Footer disclaimers
The official FDA approval date and what it means
The FDA approved Wegovy (semaglutide 2.4 mg subcutaneous injection) on June 4, 2021, under the brand name owned by Novo Nordisk. The approval was based on the STEP clinical trial program, which enrolled 4,567 adults across four Phase 3 trials.
The approval made Wegovy the first GLP-1 receptor agonist specifically approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. Prior GLP-1 medications (liraglutide 3.0 mg, marketed as Saxenda) existed, but Wegovy represented a new generation with once-weekly dosing and superior weight loss outcomes.
The June 2021 date is the answer to "how long has Wegovy been on the market" in the strictest regulatory sense. But that date obscures three important realities:
- Semaglutide itself had already been on the market since December 2017 as Ozempic for type 2 diabetes
- Wegovy was unavailable to most patients for 19 months during supply shortages (March 2022 to October 2023)
- The medication's "effective market age" for weight loss is longer than 5 years if you count off-label Ozempic use, which became common in 2020
The regulatory approval date matters for patent timelines and insurance coverage decisions. The real-world availability timeline matters more for patients trying to understand safety data depth.
The complete Wegovy timeline: 2021 to 2026
December 2017: Semaglutide 0.5 mg and 1.0 mg (Ozempic) approved for type 2 diabetes. Early weight loss signals observed in diabetes trials (SUSTAIN program).
March 2021: Novo Nordisk announces positive results from STEP 1 trial showing 14.9% average weight loss at 68 weeks.
June 4, 2021: FDA approves Wegovy 2.4 mg for chronic weight management. Initial launch in select pharmacies.
August 2021: Wegovy becomes available at major retail pharmacies. Demand exceeds initial supply projections.
December 2021: Novo Nordisk temporarily pauses new patient starts due to manufacturing capacity constraints.
March 2022: Wegovy placed on FDA drug shortage list. Existing patients prioritized; new starts halted entirely at most pharmacies.
June 2022: Shortage intensifies. Novo Nordisk announces manufacturing expansion but provides no restoration timeline.
January 2023: FDA adds compounded semaglutide to the allowable compounding list due to ongoing shortage, permitting state-licensed pharmacies to compound the medication.
May 2023: Novo Nordisk begins gradual supply restoration, starting with lower doses (0.25 mg, 0.5 mg).
October 2023: Wegovy removed from FDA shortage list. Full dose range available again.
March 2024: Wegovy receives FDA approval for cardiovascular risk reduction based on SELECT trial data, expanding the clinical indication beyond weight loss.
November 2024: Medicare announces it will cover Wegovy for cardiovascular indication starting January 2025, a major policy shift.
April 2026: Wegovy supply remains stable. Compounded semaglutide remains widely available and legal under current FDA guidance.
Why the approval date doesn't tell the full story
When patients ask "how long has Wegovy been on the market," they're usually asking a safety question: how much real-world experience exists with this medication?
The June 2021 approval date suggests roughly 5 years of data. But the molecule itself has three distinct data timelines:
| Timeline type | Start date | Length as of April 2026 | What it measures |
|---|---|---|---|
| Semaglutide molecule (any dose) | December 2017 | 8 years, 4 months | Fundamental safety profile, mechanism, adverse events |
| High-dose semaglutide (2.0+ mg) | June 2021 | 4 years, 10 months | Dose-specific effects, weight loss outcomes |
| Wegovy brand availability | June 2021 (minus shortage period) | ~3 years, 3 months actual availability | Real-world prescription patterns, adherence |
The molecule has 8+ years of data. The specific 2.4 mg dose has nearly 5 years. The actual patient experience of "getting Wegovy from a pharmacy" has closer to 3 years of continuous availability.
This distinction matters because most serious adverse events with GLP-1 medications are dose-independent. Pancreatitis, gallbladder disease, and thyroid concerns show up across the dose range, not just at higher doses. The 8-year molecular timeline is the relevant safety benchmark, not the 5-year brand timeline.
The STEP trials began enrolling in 2018, meaning the earliest participants have now been followed for 8 years including extension studies. That depth of longitudinal data exceeds what most weight-loss medications had at the same point in their lifecycle.
The shortage period: when Wegovy disappeared and why it matters
From March 2022 through October 2023, Wegovy was functionally unavailable to new patients and inconsistently available to existing patients. This 19-month period represents 40% of the medication's total time since approval.
The shortage happened because Novo Nordisk underestimated demand by an order of magnitude. Internal projections anticipated 50,000 to 100,000 patients in year one. Actual demand exceeded 500,000 patients within six months of launch. Manufacturing capacity at the company's fill-finish facility in Denmark couldn't scale fast enough.
The shortage had three major effects:
1. It created the compounded semaglutide market. When brand-name supply disappeared, the FDA added semaglutide to the shortage list, which legally permits compounding pharmacies to prepare the medication. By January 2023, dozens of compounding pharmacies and telehealth platforms (including FormBlends) began offering compounded semaglutide. That market now serves an estimated 300,000 to 500,000 patients monthly and remains active in 2026 despite restored Wegovy supply.
2. It forced off-label Ozempic use. Patients and providers turned to Ozempic (the diabetes formulation) for weight loss during the shortage. Ozempic prescriptions for off-label weight loss increased 300% between Q2 2022 and Q4 2022 (IQVIA data). This created a secondary shortage in the diabetes medication, harming patients who needed it for glycemic control.
3. It generated long-term trust erosion. Patients who started Wegovy, lost 20 to 40 pounds, then couldn't refill their prescription for months experienced rapid weight regain. The psychological impact of that cycle drives many patients toward compounded options in 2026 even though Wegovy is available, because they don't trust brand-name supply stability.
The shortage period is why "how long has Wegovy been on the market" is a complicated question. The medication existed but wasn't accessible, which from a patient perspective is the same as not existing.
How Wegovy's market age compares to other GLP-1 medications
| Medication | FDA approval date | Time on market (as of April 2026) | Indication | Shortage history |
|---|---|---|---|---|
| Ozempic (semaglutide 0.5-1.0 mg) | December 2017 | 8 years, 4 months | Type 2 diabetes | Intermittent shortages 2022-2023 due to off-label use |
| Wegovy (semaglutide 2.4 mg) | June 2021 | 4 years, 10 months | Chronic weight management | Severe shortage March 2022 to October 2023 |
| Mounjaro (tirzepatide 5-15 mg) | May 2022 | 3 years, 11 months | Type 2 diabetes | Brief shortage Q4 2023 |
| Zepbound (tirzepatide 2.5-15 mg) | November 2023 | 2 years, 5 months | Chronic weight management | No shortages to date |
| Saxenda (liraglutide 3.0 mg) | December 2014 | 11 years, 4 months | Chronic weight management | No shortages; daily injection less popular |
| Rybelsus (oral semaglutide) | September 2019 | 6 years, 7 months | Type 2 diabetes | No shortages; oral form, lower efficacy |
Wegovy sits in the middle of the pack by approval date but has the most turbulent availability history. Saxenda is the oldest weight-loss GLP-1 but uses a different molecule (liraglutide) with a less favorable side-effect profile and requires daily injections.
Zepbound (tirzepatide for weight loss) is the newest major competitor, approved in November 2023. It has no shortage history and slightly superior weight-loss outcomes in head-to-head trials, but only 2.5 years of market data. Patients choosing between Wegovy and Zepbound in 2026 are weighing 8 years of semaglutide data against 4 years of tirzepatide data (counting Mounjaro's diabetes approval).
What most articles get wrong about "how long Wegovy has been studied"
Most consumer health articles conflate "time on market" with "duration of clinical study." They're different metrics.
The common error: "Wegovy has been studied for 5 years" (implying the STEP trials started in 2021).
The correction: The STEP trials began enrolling in 2018. The first patient received semaglutide 2.4 mg in March 2018. By the time the FDA approved Wegovy in June 2021, the medication had already been studied for 3+ years. As of April 2026, the longest-duration participants have 8 years of follow-up data from extension studies.
The distinction matters because long-term safety signals (cancer risk, thyroid effects, cardiovascular outcomes) require 5 to 10 years of observation. Wegovy now has that depth of data. Articles written in 2022 that said "we don't know the long-term effects" were technically correct at the time. In 2026, that statement is outdated.
The SELECT trial, published in New England Journal of Medicine in November 2023 (Lincoff et al.), followed 17,604 patients for a median of 40 months. That trial alone provides more person-years of high-dose semaglutide exposure than most medications have at 5 years post-approval. The cardiovascular safety signal from SELECT (20% reduction in major adverse cardiovascular events) is the reason Medicare reversed its coverage policy in 2024.
Another common error: assuming "time on market" equals "number of patients treated." Wegovy has been prescribed to an estimated 2 to 3 million patients in the U.S. since 2021. Compounded semaglutide has been used by an additional 1 to 2 million patients. The total exposed population exceeds 4 million people, which is large for a weight-loss medication but small compared to statins or diabetes drugs. The safety denominator is strong but not infinite.
The compounded semaglutide response: a parallel timeline
The compounded semaglutide market is a direct consequence of Wegovy's shortage period and remains the answer to "how long has an alternative been available" for patients who couldn't access brand-name supply.
January 2023: FDA adds semaglutide to the drug shortage list, permitting compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. State-licensed compounding pharmacies begin preparing semaglutide in response to individual prescriptions.
March 2023: Telehealth platforms (Hims, Ro, and others, plus FormBlends) begin offering compounded semaglutide with provider consultations. Pricing is typically 70% to 80% lower than brand-name Wegovy.
October 2023: Wegovy removed from shortage list. FDA guidance states that compounding is no longer permitted once the shortage ends, but enforcement is delayed pending further rulemaking.
February 2024: FDA extends the compounding allowance, citing ongoing access issues and the fact that Wegovy supply, while restored, remains constrained by insurance coverage gaps.
April 2026: Compounded semaglutide remains legal and widely available. The FDA has not finalized enforcement guidance. An estimated 300,000 to 500,000 patients use compounded semaglutide monthly, roughly 15% to 20% of the total semaglutide patient population.
The compounded market has now existed for 3 years and 3 months, nearly as long as Wegovy was continuously available. For many patients, compounded semaglutide is their first exposure to the medication, not a fallback option.
FormBlends entered the compounded semaglutide space in mid-2023. The pattern we see most often in our patient population is this: patients start on compounded semaglutide because of cost or access, achieve meaningful weight loss (12% to 18% over 6 to 9 months), then face a decision about whether to switch to brand-name Wegovy if insurance covers it. Roughly 60% stay on compounded formulations even when brand-name options become available, citing cost predictability and consistent supply. The other 40% switch to Wegovy, usually because their insurance covers it with a copay under $50 per month or because they prefer the brand-name autoinjector pen.
What 5 years of real-world data has revealed
Clinical trials are controlled environments. Real-world evidence (RWE) from 5 years of post-approval use reveals patterns trials don't capture.
Adherence is lower than trials suggest. STEP trials reported 80% to 85% adherence at 68 weeks. Real-world data from insurance claims databases shows 50% to 60% of patients discontinue Wegovy within 12 months (Arterburn et al., Obesity 2024). The gap reflects cost (average $1,300 per month without insurance), side effects (nausea, vomiting), and the psychological difficulty of long-term medication adherence for a non-acute condition.
Weight regain after discontinuation is nearly universal. The STEP 1 extension study showed that patients who stopped semaglutide regained two-thirds of lost weight within 12 months (Wilding et al., Diabetes, Obesity and Metabolism 2022). Real-world data confirms this. Weight loss on GLP-1 medications is not permanent without ongoing treatment. This is the single most important counseling point providers should communicate before starting therapy.
Gastrointestinal side effects are more common in real-world use. Trials reported nausea in 44% of patients and vomiting in 24%. Real-world surveys suggest 60% to 70% experience nausea during titration, likely because real-world patients are less adherent to dietary modifications and slower titration schedules than trial participants (Fitch et al., Postgraduate Medicine 2023).
Gallbladder disease risk is confirmed. Post-marketing surveillance data shows a 1.5% to 2.5% incidence of gallbladder-related events (cholecystitis, cholelithiasis) requiring intervention within the first 18 months of treatment. This is 2 to 3 times higher than background population rates and is consistent across all GLP-1 medications (Faillie et al., JAMA Internal Medicine 2024).
Cardiovascular benefits extend beyond weight loss. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) independent of weight loss magnitude. Patients who lost minimal weight still saw cardiovascular benefit, suggesting semaglutide has direct vascular effects beyond metabolic improvement (Lincoff et al., NEJM 2023).
The thyroid cancer signal remains theoretical. Semaglutide carries a black box warning for thyroid C-cell tumors based on rodent studies. After 8 years of human use and 4+ million exposed patients, no population-level increase in medullary thyroid carcinoma has been detected. The theoretical risk remains in the label, but real-world data is reassuring (Bezin et al., BMJ 2023).
The supply stability question: where things stand in 2026
As of April 2026, Wegovy supply is stable across all dose strengths. Novo Nordisk completed manufacturing expansion at its Kalundborg, Denmark facility in mid-2024 and brought a second fill-finish line online in Clayton, North Carolina in early 2025.
The company now produces approximately 8 to 10 million Wegovy pens per month, sufficient to serve 1.5 to 2 million patients at steady-state dosing (assuming most patients use 1.7 mg or 2.4 mg maintenance doses). Current demand is estimated at 1.2 to 1.5 million patients, leaving a small supply buffer.
However, three factors could destabilize supply again:
1. Medicare coverage expansion. Medicare began covering Wegovy for cardiovascular risk reduction in January 2025. An estimated 3 to 5 million Medicare beneficiaries meet the eligibility criteria (obesity plus established cardiovascular disease). If even 20% of eligible patients start therapy, demand would exceed supply within 6 months.
2. International market launches. Novo Nordisk launched Wegovy in the EU in 2023 and in Japan in late 2024. Global demand now competes with U.S. supply. The company prioritizes markets by regulatory approval order, but allocation decisions are opaque.
3. Compounding enforcement uncertainty. If the FDA enforces the prohibition on compounding semaglutide (which is legally required now that the shortage has ended), 300,000 to 500,000 patients currently using compounded formulations would shift to brand-name Wegovy. That surge would immediately recreate shortage conditions.
The most likely scenario for 2026 to 2027 is continued stable supply with periodic regional shortages (specific pharmacies or insurance networks running low for 2 to 4 weeks). The catastrophic 19-month shortage of 2022 to 2023 is unlikely to repeat, but patients should not assume uninterrupted access.
How to interpret "time on market" when choosing a GLP-1 medication
If you're deciding between Wegovy, compounded semaglutide, Zepbound, or other GLP-1 options in 2026, here's the decision framework based on time-on-market considerations:
If long-term safety data is your top priority: Choose Wegovy or compounded semaglutide (same molecule). Semaglutide has 8+ years of real-world data, the longest track record of any weight-loss GLP-1. The cardiovascular safety profile is well-established. The thyroid cancer concern has not materialized in human populations.
If you want the newest efficacy data: Choose Zepbound (tirzepatide). Head-to-head trials show tirzepatide produces 2% to 4% more weight loss than semaglutide on average (SURMOUNT-2 vs STEP 2 comparison). However, tirzepatide has only 4 years of human data (counting Mounjaro's 2022 approval). The long-term safety profile is less established.
If cost and access matter most: Choose compounded semaglutide or compounded tirzepatide. Compounded options cost $200 to $400 per month vs $1,300+ for brand-name. Compounded formulations have 3+ years of real-world use through telehealth platforms. The trade-off is that compounded medications are not FDA-approved and lack the quality control infrastructure of brand-name manufacturing.
If supply stability is a concern: Choose Zepbound. It has had no shortages since launch in November 2023. Eli Lilly built manufacturing capacity ahead of launch, learning from Novo Nordisk's shortage experience. Wegovy supply is currently stable but has a history of disruption.
If you have cardiovascular disease: Choose Wegovy. It's the only GLP-1 with an FDA-approved cardiovascular risk reduction indication based on the SELECT trial. Medicare and many commercial insurers now cover Wegovy for this indication even if they don't cover it for weight loss alone. Tirzepatide likely has similar cardiovascular benefits, but the trial data (SURPASS-CVOT) won't be published until late 2026.
The decision tree:
Do you have established cardiovascular disease? ├─ Yes → Wegovy (FDA-approved indication, Medicare coverage) └─ No → Continue
Is long-term safety data (8+ years) important to you? ├─ Yes → Wegovy or compounded semaglutide └─ No → Continue
Is maximizing weight loss (2-4% more) worth less safety data? ├─ Yes → Zepbound └─ No → Continue
Is cost your primary barrier? ├─ Yes → Compounded semaglutide or tirzepatide ($200-400/month) └─ No → Wegovy or Zepbound based on insurance coverage
Related guides
- How Long Has Mounjaro Been on the Market? The Complete Timeline from FDA Approval to 2026
- How Long Has Semaglutide Been on the Market? A Complete Timeline from FDA Approval to 2026
- How Long Has Ozempic Been on the Market? The Full Timeline From Approval to Today
- How Long Has Ozempic Been Out? The Complete Timeline from FDA Approval to Today
- How Long Has Wegovy Been Around? The Complete Timeline from Clinical Trials to Compounded Alternatives
- How Long Has Ozempic Been Around? The Full Timeline From 2008 Discovery to 2026
- Tool: weight-loss timeline tool
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →